Alon Ruth 4

What Happened
Alon Ruth, a director of Silexion Therapeutics Corp., received two compensation awards on Feb 20, 2026: 9,091 fully vested restricted share units (RSUs) that were immediately settled for underlying ordinary shares, and an option grant covering 10,685 shares. The Form 4 shows $0.00 as the acquisition price for both items (this reflects the grant/compensation reporting on the form, not the market value).

Key Details

• Transaction date(s): 2026-02-20 (reported on Form 4 filed 2026-02-23).
• Items granted: 9,091 shares (RSUs immediately settled for shares) and options to purchase 10,685 shares.
• Price shown on form: $0.00 for both entries (compensation grant reporting).
• Vesting/expiration for options: options vest in full on the one‑year anniversary of the grant and expire on the ten‑year anniversary (footnote F3).
• Footnotes: F1 confirms RSUs were fully vested and immediately settled; F2 describes the option grant; F4 notes certain reported holdings/rows are informational only.
• Post‑transaction holdings: not specified in the excerpt provided.

Context
These transactions are compensation grants to a director (coded “A” for award/grant), which are common for board service and do not represent an open‑market purchase or sale. The option is a derivative award that will vest after one year; no exercise or sale is reported. The $0.00 amount on the filing indicates grant reporting and should not be interpreted as market value.